BHCM
CCCC icon

Brevan Howard Capital Management’s C4 Therapeutics CCCC Stock Holding History

Brevan Howard Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-92,647
Closed -$244K – 2130
2026
Q1 		$244K Buy
+92,647
New +$218K ﹤0.01% 1779
2024
Q3 		– Sell
-33,511
Closed -$155K – 1165
2024
Q2 		$155K Buy
33,511
+17,985
+116% +$107K ﹤0.01% 929
2024
Q1 		$127K Buy
+15,526
New +$120K ﹤0.01% 865

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brevan Howard Capital Management's CCCC Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 92,647 shares — an estimated $244K sold.

Brevan Howard Capital Management first reported a position in CCCC in Q1 2024 and held it in 3 quarters. The position peaked at $244K in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 92,647 C4 Therapeutics shares in Q2 2026, an estimated $244K.
  • Brevan Howard Capital Management first reported a position in C4 Therapeutics in Q1 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's C4 Therapeutics position peaked at $244K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.